A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival

Blood

Volumn 105, Issue 11, 2005, Pages 4484-4491

  Alvi, Azra J ^b   Austen, Belinda ^b   Weston, Victoria J ^b   Fegan, Christopher ^b   MacCallum, David ^b   Gianella Borradori, Athos ^b   Lane, David P ^b   Hubank, Mike ^b   Powell, Judith E ^b   Wei, Wenbin ^b   Taylor, A Malcolm R ^b   Moss, Paul A H ^b   Stankovic, Tatjana ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RNA POLYMERASE II; ROSCOVITINE;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA TRANSLATION; TRANSCRIPTION REGULATION;

EID: 21144435503     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2713     Document Type: Article

References (29)

1. Pangalis GA, Vassilakopoulos TP, Dimopoulou MN, Siakantaris MP, Kontopidou F, Angelopoulou MK. B-chronic lymphocytic leukemia: practical aspects. Hematol Oncol. 2002;20:103-146.
2. Keating MJ, Chiorazzi N, Messmer B, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology 2003. American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2003. 153-175.
3. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AMR, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98:814-822.
4. Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood. 2002;99:300-309.
5. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004;23:2934-2949.
6. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene. 2003;22:6609-6620.
7. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors: from starfish oocytes to clinical trials. Acc Chem Res. 2003;36:417-425.
8. Fischer PM, Gianella-Borradori A. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 2003;12:955-970.
9. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-Roscovitine). Int J Cancer. 2002;102:463-468.
10. de la Motte S, Gianella-Borradori A. Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther. 2004;42:232-239.
11. Hahntow IN, Schneller F, Oelsner M, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia. 2004;18:747-755.
12. Stankovic T, Hubank M, Cronin D, et al. Microarray analysis reveals that TP53 and ATM mutant B-CLLs share a defect in activation of pro-apoptotic responses following DNA damage but are distinguished by major differences in activation of pro-survival responses. Blood. 2004;103:291-300.
13. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high-density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185-193.
14. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.
15. Tusher, VG, Tibshirani, R, Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121.
16. Storey JD, Tibshirani R. Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol. 2003;224:149-157.
17. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004;23:2797-2808.
18. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002;99:1885-1893.
19. Iglesias-Serret D, Piqué M, Gil J, Pons G, López JM. Transcriptional and translational control of Mcl-1 during apoptosis. Arch Biochem Biophys. 2003;417:141-152.
20. Kim YK, Bourgeois CF, Isel C, Churcher MJ, Karn J. Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol. 2002;22:4622-4637.
21. Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of chronic lymphocytic leukemia patients induces a p53-dependent gene expression response. Blood. 2004;104:1428-1434.
22. Komarnitsky P, Cho E-J, Buratowski S. Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. Genes Dev. 2000;14:2452-2460.
23. Lin PS, Dubois M-F, Dahmus ME. TFIIF-associating carboxyl-terminal domain phosphatase dephosphorylates phosphoserines 2 and 5 of RNA polymerase II. J Biol Chem. 2002;277:45949-45956.
24. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxystaurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukaemia. Blood. 2000;96:393-397.
25. Nijhawan D, Fang M, Traer E, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003;17:1475-1486.
26. Cuconati A, Mukherjee C, Perez D, White E. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 2003;23:2922-2932.
27. Weston VJ, Austen B, Wei W, et al. Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukaemia frequently involves increased NF-kappaB survival pathway signaling. Blood. 2004;104:1465-1473.
28. Ohta K, Iwai K, Kasahara Y, et al. Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-X and Mcl-1, in human peripheral blood and lymphoid tissues. Int Immunol. 1995;11:1817-1825.
29. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2001;2:1-11.